Kanna Is Not Mesembrine: Alkaloids, Fermentation, SERT, PDE4, and Human Evidence

Last reviewed September 15, 2026. Educational content for adults 21+. This article is not medical advice and does not recommend a dose, treatment, drug substitution or combination.

The short answer

The phrase kanna alkaloids describes a chemically diverse group in the South African succulent commonly sold as Sceletium tortuosum. Royal Botanic Gardens, Kew currently accepts the name Mesembryanthemum tortuosum L. and treats Sceletium tortuosum (L.) N.E.Br. as a synonym. Both names therefore appear in research and commerce.

Mesembrine is only one alkaloid. Mesembrenone, mesembrenol, Δ7-mesembrenone, mesembranol, epimesembranol, and structurally different Sceletium alkaloids can also occur. Their proportions vary greatly across plants and products. One 151-specimen analysis found five broad chemical clusters, including a cluster without detectable mesembrine-type alkaloids and clusters dominated by mesembrenol, mesembrine, or mesembrenone.

In laboratory assays, mesembrine bound strongly to the serotonin transporter, while mesembrenone showed both serotonin-transporter and phosphodiesterase-4 activity. A separate high-mesembrine extract showed monoamine-releasing behavior in vitro. These results do not make kanna an SSRI, antidepressant, PDE4 medicine, or replacement for any prescription product. An isolated target result is not a clinical indication.

Human evidence remains preparation-specific and small. One standardized extract has been studied in healthy volunteers for tolerability, brain imaging, and selected cognitive or stress tasks. Those studies do not establish effectiveness for depression, anxiety disorders, dementia, or another disease. Published human plasma pharmacokinetic profiles for isolated mesembrine-type alkaloids were not located in this review; current metabolism evidence comes mainly from rat urine and pooled human-liver preparations.

1. Begin with botanical identity

Kanna and kougoed are common names, not complete chemical descriptions. Kew identifies Mesembryanthemum tortuosum as an accepted Aizoaceae species native to South Africa’s Cape Provinces. The name Sceletium tortuosum remains common in published pharmacology, product labels, and patents.

That naming history matters for quality control. Other Sceletium species do not necessarily contain the same alkaloids. A chemotaxonomic study found that not all examined species contained the mesembrine-type profile commonly associated with S. tortuosum. A label that says only “kanna” cannot establish species, plant part, fermentation state, extract composition, or alkaloid quantity.

Sources: Kew accepted name, Kew synonym record, and Patnala and Kanfer chemotaxonomy study.

2. Separate the preparation before discussing an effect

“Ethanolic extract” describes a manufacturing process, not necessarily ethanol as a finished-product ingredient. “Fermented” describes a process, not a standardized chemical outcome. “10:1 extract” describes a manufacturing ratio only when the starting material, solvent, yield, and basis of calculation are defined; it does not state the amount of mesembrine.

3. The principal molecules are related—but not interchangeable

The best-studied constituents belong to the mesembrine-type alkaloid family. They contain nitrogen and are correctly called alkaloids, unlike kava’s principal kavalactones. Their related ring systems carry different oxidation states, double-bond positions, and stereochemistry.

Molecular formulas alone cannot distinguish positional isomers or stereoisomers. Mesembrenone and Δ7-mesembrenone share a formula but place unsaturation differently. Mesembranol and epimesembranol share connectivity or formula features while differing in spatial configuration. Analytical methods therefore need authentic standards, chromatographic separation, and structural confirmation—not just a matching molecular mass.

Identity sources: PubChem mesembrine, PubChem mesembrenone, and validated HPLC method.

4. Natural chemotypes vary dramatically

In 2012, researchers used GC–MS to examine 151 wild S. tortuosum specimens from 31 South African localities and eight commercial products. Total alkaloids in the wild samples ranged from 0.11% to 1.99% of dry weight. Statistical clustering produced five broad chemotypes:

• Chemotype A: no detected mesembrine-type alkaloids in the reported analysis;
• Chemotype B: mesembrenol-dominant;
• Chemotype C: mesembrine-dominant;
• Chemotype D: a mixed/intermediate profile; and
• Chemotype E: mesembrenone-dominant.

The percentage ranges in those clusters were proportions within the measured alkaloid profile, not percentages of the entire plant. Mesembrine was the leading alkaloid in most—but not all—of the eight commercial products examined.

This study proves variability in the sampled material. It does not create a permanent A-to-E classification for every cultivated lot, and it does not show that one chemotype reliably causes one subjective experience. Geography, genetics, season, harvest, drying, storage, and processing can all change the measured profile.

Primary source: Shikanga et al., 2012.

5. Fermentation does not have one universal chemical arrow

The popular sentence “fermentation converts mesembrine into Δ7-mesembrenone” is too absolute.

2009 controlled preparation

Patnala and Kanfer simulated kougoed preparation using aerial material and also studied purified mesembrine hydrochloride. In one fermentation experiment, mesembrine decreased from 1.33% to 0.05%, while Δ7-mesembrenone rose from undetected to 0.11%. The authors also found mesembrine instability under light, heat, water, and fermentation conditions.

2019 controlled fermentation

Chen and Viljoen used validated UPLC–MS before and after controlled fermentation. Their samples moved in the opposite headline direction: mesembrine increased from undetected–1.6 micrograms/mL to 7.40–20.8 micrograms/mL, while mesembrenone decreased. Total measured alkaloids increased.

2024 microbiome work

Koroleva and colleagues monitored a nine-day fermentation using UHPLC–MS and metagenomics. Significant chemical changes appeared after day five as Fusarium became prominent. In sterilized biomass inoculated with individual fungi, one Fusarium species increased epimesembranol and decreased several other alkaloids, supporting a role for microbial metabolism.

What the conflict teaches

Fermentation is not one reaction in one flask. Starting chemotype, plant moisture, light, temperature, oxygen, time, endogenous enzymes, microorganisms, drying, and analytical method can shift the outcome. Oxidation may move one molecule toward a more unsaturated product; reduction may move another toward an alcohol. Evaporation can also concentrate material without biosynthesizing more molecules.

Therefore, “fermented kanna” is not a quantitative specification. A defensible product description needs the organism identity, plant part, process, batch, analytical panel, method, units, and measured alkaloid profile.

Sources: Patnala and Kanfer, 2009, Chen and Viljoen, 2019, and Koroleva et al., 2024.

6. Serotonin transporter: what the assay actually measured

The serotonin transporter, abbreviated SERT or 5-HTT, sits in neuronal membranes and returns serotonin from the extracellular space to the presynaptic cell using ion gradients. Blocking that transport process can slow serotonin clearance from the synaptic region. It does not mean that serotonin is literally “created,” and it does not make every SERT-binding compound a clinically proven antidepressant.

In Harvey and colleagues’ 2011 experiments, a standardized extract and three isolated alkaloids were tested. Mesembrine showed the highest affinity for SERT, with a reported inhibition constant of 1.4 nM; mesembrenone and mesembrenol were reported at 27 nM and 63 nM. The standardized extract inhibited serotonin uptake with a reported IC50 of 4.3 micrograms/mL.

Ki and IC50 are not interchangeable quantities. Ki estimates binding affinity under a model; IC50 is the concentration producing half-maximal inhibition in a particular assay. Neither value is a human blood concentration, a serving recommendation, a clinical response threshold, or a safety limit.

Primary source: Harvey et al., 2011.

7. PDE4: the second target, without the shortcut

Phosphodiesterase-4 enzymes degrade cyclic adenosine monophosphate, or cAMP. cAMP is an intracellular messenger that transfers signals from receptors to enzymes and transcription machinery. Inhibiting PDE4 can allow cAMP signals to last longer, but the result depends on PDE4 subtype, cell type, tissue exposure, and competing pathways.

In the same 2011 work, the standardized extract inhibited PDE4 with an IC50 of 8.5 micrograms/mL. Mesembrenone was the most active of the three isolated alkaloids in the reported PDE4 assay, with an IC50 of about 470 nM. Mesembrine and mesembrenol were substantially weaker in that assay.

This creates a useful compound-level distinction: mesembrine carried the strongest SERT-affinity result, while mesembrenone carried the strongest PDE4 result among the tested alkaloids. It does not prove that a mesembrenone-dominant product improves cognition or that a mesembrine-dominant product treats a mood disorder.

Pharmaceutical comparator boundary

Fluoxetine is an FDA-approved SSRI with product-specific indications, dosing, pharmacokinetics, manufacturing controls, and labeling. Roflumilast and apremilast are FDA-approved PDE4 inhibitors used in defined medical contexts. Kanna extracts are not approved versions of those drugs, and sharing one assay target does not establish equal selectivity, tissue exposure, efficacy, safety, or clinical use.

The inactive ingredients of those pharmaceutical products require a separate, label-version-specific formulation audit; ingredients should not be merged across manufacturers or versions.

Sources: Harvey et al., 2011 and current fluoxetine label.

8. A high-mesembrine extract produced another in-vitro result

A 2016 study examined Trimesemine, a proprietary high-mesembrine extract. In the researchers’ cellular systems, the extract behaved as a monoamine-releasing agent and findings were interpreted as involving vesicular monoamine transporter 2, or VMAT2, rather than simple SERT inhibition alone.

VMAT2 packages monoamines—including serotonin, dopamine, and norepinephrine—into intracellular vesicles. Changing vesicular handling can alter the pool available for release. But the 2016 result belongs to that selected high-mesembrine extract and assay. It should not be rewritten as “all kanna releases dopamine” or as proof of an effect magnitude in humans.

This finding also shows why “kanna is an SSRI” is incomplete. Different extracts can carry different ratios, and different assays can reveal transporter binding, uptake inhibition, vesicular effects, or unrelated targets. The correct statement names the exact preparation and assay.

Primary source: Coetzee et al., 2016.

9. Metabolism: what is human, what is not

The most detailed metabolism study did not administer purified mesembrine or mesembrenone to a human pharmacokinetic cohort. Researchers analyzed rat urine and incubated the compounds with pooled human-liver preparations.

Both alkaloids underwent combinations of:

• O-demethylation;
• N-demethylation;
• reduction or dihydration;
• hydroxylation; and
• glucuronide or sulfate conjugation of phenolic metabolites.

In recombinant-enzyme experiments, mesembrine O-demethylation involved CYP1A2, CYP2B6, CYP2C19, and CYP2D6; its N-demethylation involved those enzymes plus CYP3A4 and CYP3A5. Mesembrenone O-demethylation involved CYP2C9, CYP2C19, and CYP2D6; N-demethylation involved CYP2C19, CYP2D6, and CYP3A4.

Those enzyme assignments identify possible metabolic routes. They do not show that kanna clinically inhibits those enzymes, establish the fraction carried by each enzyme in a person, or quantify an interaction with a medicine. Rat urinary metabolites and pooled liver preparations are not a human plasma concentration-time study.

Primary source: Meyer et al., 2015.

10. What has actually been observed in humans

Three-month tolerability trial

Nell and colleagues randomized 37 healthy adults to placebo or one of two amounts of a standardized extract for three months. The authors reported that both studied extract groups were well tolerated. Because the groups contained only 12, 12, and 13 participants, this trial cannot establish rare-event safety, safety in pregnancy, long-term safety, interaction safety, or safety of different products.

Acute pharmaco-fMRI study

Terburg and colleagues enrolled 16 healthy, medication-free university students, aged 18–21, in a double-blind crossover study. Each received a single 25 mg standardized-extract capsule and placebo on separate visits. One participant was excluded from task analyses because of poor performance. Under one low-perceptual-load fearful-face contrast, amygdala BOLD reactivity was lower after the extract; amygdala–hypothalamus connectivity was also lower in a follow-up analysis. The study found no general subjective mood effect.

BOLD is a blood-oxygenation signal, not a direct serotonin measurement and not proof of treatment benefit. The study tested one acute imaging response in healthy young adults, not people diagnosed with an anxiety disorder.

Exploratory cognition study

Chiu and colleagues used a randomized, double-blind, placebo-controlled crossover design in 21 cognitively healthy adults with a mean age of about 55. Participants received the standardized extract or placebo for three weeks. Selected measures of cognitive flexibility and executive function differed from placebo. The small sample, short duration, multiple endpoints, and healthy population make the findings exploratory; they do not demonstrate prevention or treatment of dementia.

The studied Zembrin formulation

The fMRI paper identifies the active ingredient as an aqueous-ethanolic extract of above-ground cultivated material, using purified water and ethanol during extraction and spray-drying the extract onto maltodextrin. Each active gelatin capsule contained 25 mg of the extract plus unspecified inert excipients. This is the research formulation described in that paper—not a complete ingredient statement for every historical or commercial product.

Human sources: Nell et al., 2013, Terburg et al., 2013, and Chiu et al., 2014.

11. Serotonergic interactions: plausible concern, missing direct measurements

FDA-approved fluoxetine labeling warns that SSRIs can precipitate potentially life-threatening serotonin syndrome, particularly with other serotonergic agents or medicines that impair serotonin metabolism. The recognized syndrome can include agitation or confusion, sweating, fever, rapid heart rate, unstable blood pressure, tremor, clonus, hyperreflexia, rigidity, seizures, vomiting, diarrhea, and coma.

Severe serotonin toxicity can become fatal through extreme hyperthermia, sustained muscle activity, rhabdomyolysis, metabolic acidosis, kidney injury, clotting abnormalities, respiratory failure, or multiorgan failure. That is established pharmacology for serotonin toxicity generally.

For kanna, the link is more limited:

1. specific alkaloids and extracts inhibit SERT in vitro;
2. one high-mesembrine extract showed monoamine-releasing activity in vitro;
3. direct controlled human interaction studies with SSRIs, SNRIs, MAO inhibitors, tramadol, dextromethorphan, stimulants, linezolid, lithium, or serotonergic combinations were not located in this review; and
4. no universal kanna exposure capable of causing serotonin toxicity or death can be derived from the available evidence.

It is therefore incorrect to state either “kanna plus an SSRI will cause serotonin syndrome” or “the combination is proven safe.” The defensible statement is that overlapping serotonergic mechanisms create a biologically plausible interaction concern that lacks adequate product-specific human quantification. People using serotonergic medicines should discuss kanna with the prescribing clinician or pharmacist rather than changing medication on their own.

Emergency symptoms—especially high fever, marked agitation or confusion, muscle rigidity, repeated clonus, seizure, collapse, breathing difficulty, or inability to wake—require emergency care. This is recognition guidance, not a home-treatment protocol.

Authoritative comparator source: DailyMed fluoxetine label.

12. Compact history with attribution boundaries

• Before colonial documentation: Khoe and San communities held traditional knowledge of kanna/kougoed preparations. Exact antiquity cannot be converted into a clinical claim.
• Seventeenth century: later ethnobotanical reviews trace early written colonial descriptions to the 1600s. These are historical reconstructions and should ultimately be linked to archival transcriptions.
• 1753: Linnaeus published the name Mesembryanthemum tortuosum; Kew currently accepts this name.
• 1898: later scientific histories credit Meiring with isolating an alkaloidal fraction and testing it in animals.
• 1914: Zwicky’s dissertation described alkaloids and used the name “mesembrin,” but early formula and structural assignments were later corrected.
• Twentieth century: isolation, structural elucidation, and synthesis separated mesembrine from related alkaloids.
• 2009–2024: analytical fermentation studies produced preparation-dependent—and sometimes opposing—alkaloid shifts.
• 2011 onward: modern target assays and small human studies evaluated specific standardized extracts.

This is a compact history rather than a complete archival reconstruction. Deeper work must distinguish first isolation, correct structure assignment and first synthesis while identifying Indigenous knowledge holders and later investigators without collapsing their roles.

History anchors: Kew taxonomy, Smith et al. review, and Reddy et al., 2024 bibliometric review.

13. Patent-family snapshot—kept separate from products

Two PCT patent families illustrate why patent claims, optional specifications, worked examples and marketed products must remain separate. They do not establish that every described embodiment was manufactured or marketed.

Patent treatment language records what applicants sought to protect; it is not clinical proof. Optional specification lists are not “ingredients.” Process water, ethanol, nutrients, soil treatments, or reagents are not final-product constituents unless a separate manufacturing or analytical record confirms them. Worked examples remain separate from independent claims and from marketed formulations.

Patent sources: WO2010106495A1 and WO2014155351A1.

14. What is known, uncertain, and not established

15. Three related Kiody guides

• What Is Kanna? — botanical identity, formats, labels, and batch documentation.
• What Is Kava? — a chemically different botanical whose principal compounds are kavalactones, not alkaloids.
• Kiody Learning Center — the broader source-linked educational index.

These links were live-checked September 15, 2026. Cross-linking does not imply pharmacological equivalence.

Frequently asked questions

Is Kanna the same as mesembrine?

No. Kanna is a botanical material that can contain multiple alkaloids and many non-alkaloid constituents. Mesembrine is one specific alkaloid. Its abundance varies among plants, preparations and extracts.

Is Kanna an SSRI?

No. Some isolated Kanna alkaloids and standardized extracts affected the serotonin transporter in laboratory assays, but that does not make Kanna an FDA-approved selective serotonin reuptake inhibitor or establish equivalent selectivity, exposure, dosing, benefits or risks.

What is mesembrenone?

Mesembrenone is a mesembrine-type Kanna alkaloid. In one set of laboratory assays it showed serotonin-transporter activity and stronger PDE4 inhibition than the other isolated Kanna alkaloids tested. Those are target-level findings, not demonstrated clinical effects.

Does fermentation always increase Δ7-mesembrenone?

No. Controlled studies have reported different—and sometimes opposing—changes. Starting material, time, moisture, temperature, microorganisms, drying and analytical methods can all influence the measured profile.

Are human Kanna pharmacokinetics known?

Not adequately at the individual-alkaloid level. Small human studies have evaluated particular standardized extracts, but this review did not locate complete human plasma concentration-time profiles for isolated mesembrine-type alkaloids.

Can Kanna be combined with antidepressants?

Direct controlled human interaction data are inadequate. Laboratory serotonin-transporter findings create a biologically plausible concern, but do not quantify a universal interaction. People taking serotonergic medicines should consult their prescriber or pharmacist and should not change prescribed treatment on their own.

Does a 10:1 extract ratio state mesembrine content?

No. An extract ratio describes a manufacturing relationship only when the starting material, solvent, yield and calculation basis are defined. It does not by itself report mesembrine, mesembrenone or total-alkaloid content.

What should a Kanna COA show?

A useful certificate of analysis should match the lot and sample type, identify the method and reference standards, report units clearly, distinguish individual alkaloids when claimed, and state detection or quantification limits. A COA supports only the tests and sample reported; it does not prove universal purity or safety.